Cargando…

Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics

Aberrations in the cyclin-dependent kinase (CDK) pathways that regulate the cell cycle restriction point contribute to genomic instability and tumor proliferation, and can be targeted by recently developed CDK inhibitors. We therefore investigated the clinical correlates of CDK4/6 and CDKN2A/B abnor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Shumei, Schwaederle, Maria, Daniels, Gregory A, Piccioni, David, Kesari, Santosh, Bazhenova, Lyudmila, Shimabukuro, Kelly, Parker, Barbara A, Fanta, Paul, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614867/ https://www.ncbi.nlm.nih.gov/pubmed/25695927 http://dx.doi.org/10.1080/15384101.2015.1014149

Ejemplares similares

Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer
por: Schwaederle, Maria, et al.
Publicado: (2015)

Cyclin alterations in diverse cancers: outcome and co-amplification network
por: Schwaederlé, Maria, et al.
Publicado: (2014)

Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology
por: Patel, Sandip P., et al.
Publicado: (2015)

Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics
por: Parish, A, et al.
Publicado: (2015)

Telomerase Reverse Transcriptase Promoter Alterations Across Cancer Types as Detected by Next-Generation Sequencing: A Clinical and Molecular Analysis of 423 Patients
por: Schwaederle, Maria, et al.
Publicado: (2017)

Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
por: Schwaederle, Maria, et al.
Publicado: (2016)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies
por: Shayeb, Akram Mesleh, et al.
Publicado: (2023)

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival
por: Kato, Shumei, et al.
Publicado: (2019)

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
por: Botta, Gregory P., et al.
Publicado: (2021)

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
por: Helsten, Teresa, et al.
Publicado: (2015)

Genomic landscape of salivary gland tumors
por: Kato, Shumei, et al.
Publicado: (2015)

The paradox of cancer genes in non-malignant conditions: implications for precision medicine
por: Adashek, Jacob J., et al.
Publicado: (2020)

Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies
por: Kato, Shumei, et al.
Publicado: (2018)

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients
por: Heestand, Gregory M., et al.
Publicado: (2017)

Liquid biopsy: current technology and clinical applications
por: Nikanjam, Mina, et al.
Publicado: (2022)

Of Mice, Not Men: When the Bench-to-Bedside Bridge Is Broken
por: Nikanjam, Mina, et al.
Publicado: (2022)

Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors
por: Jardim, Denis L F, et al.
Publicado: (2022)

Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis
por: Shaya, Justin, et al.
Publicado: (2023)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

HER2 expression status in diverse cancers: review of results from 37,992 patients
por: Yan, Min, et al.
Publicado: (2015)

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
por: Patel, Hitendra, et al.
Publicado: (2019)

Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach
por: Kato, Shumei, et al.
Publicado: (2017)

Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy
por: Krishnamurthy, Nithya, et al.
Publicado: (2022)

Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience
por: Louie, Bryan H., et al.
Publicado: (2022)

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐free DNA in invasive gliomas after treatment
por: Okamura, Ryosuke, et al.
Publicado: (2021)

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
por: Sicklick, Jason K., et al.
Publicado: (2019)

TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [(18)F] fluorodeoxyglucose ((18)F-FDG PET)
por: Chang, Geraldine H., et al.
Publicado: (2018)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

The Conundrum of Genetic “Drivers” in Benign Conditions
por: Kato, Shumei, et al.
Publicado: (2016)

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers
por: Okamura, Ryosuke, et al.
Publicado: (2020)

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer
por: Tsigelny, Igor F., et al.
Publicado: (2015)

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types
por: Schwaederle, Maria, et al.
Publicado: (2015)

Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies
por: Goodman, Aaron M., et al.
Publicado: (2017)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease
por: Cohen, Philip R., et al.
Publicado: (2017)

Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
por: Cohen, Philip R, et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Cyclin-dependent kinase inhibitors in malignant hematopoiesis
por: Schirripa, Alessia, et al.
Publicado: (2022)

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies
por: Kato, Shumei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_r17odftef1e624esf64b2i72nv